Results 221 to 230 of about 4,357,163 (359)

Why do BCL-2 inhibitors work and where should we use them in the clinic? [PDF]

, 2017
Joan Montero, Antony Letai
openalex   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

436 Immune checkpoint inhibitors in sinonasal squamous cell carcinoma [PDF]

Alan Wayne Jones, Shyam Kankotia, Zara Orozco, Robert Hsu, Jorge J. Nieva, Jacob Thomas   +5 more
openalex   +1 more source

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation [PDF]

, 2018
Julio Pascual, Stefan P. Berger, Oliver Witzke, Hélio Tedesco‐Silva, Shamkant Mulgaonkar, Yasir Qazi, Steven J. Chadban, Federico Oppenheimer, Claudia Sommerer, Rainer Oberbauer, Yoshihiko Watarai, Christophe Legendre, Franco Citterio, Mitchell L. Henry, Titte R. Srinivas, Wen‐Lin Luo, AnaMaria Marti, Peter Bernhardt, Flavio Vincenti, on behalf of the TRANSFORM Investigators   +19 more
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Structural insights into the development of inhibitors for inositol phosphate kinases. [PDF]

FEBS Lett
Wang H.
europepmc   +1 more source

461 Circadian control of the tumor immune microenvironment determines immune checkpoint inhibitor efficacy [PDF]

Jake Lichterman, Tarun Srinivasan, Ruheng Wang, Chaitanya Dende, Mitchell S. von Itzstein, Jialiang Liu, Jorge H Ramírez, Wenling Li, Laura Coughlin, Nicole Poulides, Parastoo Sabaeifard, Tian Zhang, Hans J. Hammers, Xin Li, Bret M. Evers, Xiaowei Zhan, David E. Gerber, Lora V. Hooper, Andrew Y. Koh   +18 more
openalex   +1 more source

Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature [PDF]

, 2018
Alessandra Pannunzio, Mauro Coluccia
openalex   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source